Elanco Animal Health, Inc. Aktie News

INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

Elanco Animal Health Incorporated (ELAN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Elanco Animal Health earns a buy rating, driven by robust product innovation, commercial execution, and a credible deleveraging plan. ELAN's 'Big 6' innovation portfolio is set to contribute ~$1.1 billion in 2026 revenue, supporting margin expansion and portfolio renewal. Credelio Quattro and Zenrelia demonstrate ELAN's ability to capture share from incumbents, with rapid adoption and strong se...

INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.

Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age against canine atopic dermatitis and allergic dermatitis for 6 to 8 weeks of treatment, as needed USDA approval of Befrena reinforces Elanco's commitment to going beyond to deliver differentiated,...

Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional Approval of Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first for companion animals against New World screwworm Action follows previous Emergency...

Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript

Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.